127 related articles for article (PubMed ID: 30219827)
1. PI4KIII inhibitor enviroxime impedes the replication of the hepatitis C virus by inhibiting PI3 kinases.
Delang L; Harak C; Benkheil M; Khan H; Leyssen P; Andrews M; Lohmann V; Neyts J
J Antimicrob Chemother; 2018 Dec; 73(12):3375-3384. PubMed ID: 30219827
[TBL] [Abstract][Full Text] [Related]
2. Coxsackievirus mutants that can bypass host factor PI4KIIIβ and the need for high levels of PI4P lipids for replication.
van der Schaar HM; van der Linden L; Lanke KH; Strating JR; Pürstinger G; de Vries E; de Haan CA; Neyts J; van Kuppeveld FJ
Cell Res; 2012 Nov; 22(11):1576-92. PubMed ID: 22945356
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target.
Vaillancourt FH; Brault M; Pilote L; Uyttersprot N; Gaillard ET; Stoltz JH; Knight BL; Pantages L; McFarland M; Breitfelder S; Chiu TT; Mahrouche L; Faucher AM; Cartier M; Cordingley MG; Bethell RC; Jiang H; White PW; Kukolj G
J Virol; 2012 Nov; 86(21):11595-607. PubMed ID: 22896614
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity.
Bianco A; Reghellin V; Donnici L; Fenu S; Alvarez R; Baruffa C; Peri F; Pagani M; Abrignani S; Neddermann P; De Francesco R
PLoS Pathog; 2012; 8(3):e1002576. PubMed ID: 22412376
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity.
Arita M; Kojima H; Nagano T; Okabe T; Wakita T; Shimizu H
J Virol; 2011 Mar; 85(5):2364-72. PubMed ID: 21177810
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C Virus Subverts Human Choline Kinase-α To Bridge Phosphatidylinositol-4-Kinase IIIα (PI4KIIIα) and NS5A and Upregulates PI4KIIIα Activation, Thereby Promoting the Translocation of the Ternary Complex to the Endoplasmic Reticulum for Viral Replication.
Wong MT; Chen SS
J Virol; 2017 Aug; 91(16):. PubMed ID: 28566381
[TBL] [Abstract][Full Text] [Related]
7. Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells.
Wolfisberg R; Holmbeck K; Nielsen L; Kapoor A; Rice CM; Bukh J; Scheel TKH
J Virol; 2019 Oct; 93(19):. PubMed ID: 31292246
[TBL] [Abstract][Full Text] [Related]
8. Mapping of functional domains of the lipid kinase phosphatidylinositol 4-kinase type III alpha involved in enzymatic activity and hepatitis C virus replication.
Harak C; Radujkovic D; Taveneau C; Reiss S; Klein R; Bressanelli S; Lohmann V
J Virol; 2014 Sep; 88(17):9909-26. PubMed ID: 24920820
[TBL] [Abstract][Full Text] [Related]
9. Discovery of selective small molecule type III phosphatidylinositol 4-kinase alpha (PI4KIIIα) inhibitors as anti hepatitis C (HCV) agents.
Leivers AL; Tallant M; Shotwell JB; Dickerson S; Leivers MR; McDonald OB; Gobel J; Creech KL; Strum SL; Mathis A; Rogers S; Moore CB; Botyanszki J
J Med Chem; 2014 Mar; 57(5):2091-106. PubMed ID: 23944386
[TBL] [Abstract][Full Text] [Related]
10. The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A.
Reiss S; Harak C; Romero-Brey I; Radujkovic D; Klein R; Ruggieri A; Rebhan I; Bartenschlager R; Lohmann V
PLoS Pathog; 2013 May; 9(5):e1003359. PubMed ID: 23675303
[TBL] [Abstract][Full Text] [Related]
11. NS5A inhibitors impair NS5A-phosphatidylinositol 4-kinase IIIα complex formation and cause a decrease of phosphatidylinositol 4-phosphate and cholesterol levels in hepatitis C virus-associated membranes.
Reghellin V; Donnici L; Fenu S; Berno V; Calabrese V; Pagani M; Abrignani S; Peri F; De Francesco R; Neddermann P
Antimicrob Agents Chemother; 2014 Dec; 58(12):7128-40. PubMed ID: 25224012
[TBL] [Abstract][Full Text] [Related]
12. The role of phosphatidylinositol 4-kinases and phosphatidylinositol 4-phosphate during viral replication.
Delang L; Paeshuyse J; Neyts J
Biochem Pharmacol; 2012 Dec; 84(11):1400-8. PubMed ID: 22885339
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of a replicon-based phenotypic assay for assessing HCV NS4B from clinical isolates.
Rajyaguru S; Yang H; Martin R; Miller MD; Mo H
Antiviral Res; 2013 Nov; 100(2):328-36. PubMed ID: 24013002
[TBL] [Abstract][Full Text] [Related]
14. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment.
Reiss S; Rebhan I; Backes P; Romero-Brey I; Erfle H; Matula P; Kaderali L; Poenisch M; Blankenburg H; Hiet MS; Longerich T; Diehl S; Ramirez F; Balla T; Rohr K; Kaul A; Bühler S; Pepperkok R; Lengauer T; Albrecht M; Eils R; Schirmacher P; Lohmann V; Bartenschlager R
Cell Host Microbe; 2011 Jan; 9(1):32-45. PubMed ID: 21238945
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus NS5A protein interacts with phosphatidylinositol 4-kinase type IIIalpha and regulates viral propagation.
Lim YS; Hwang SB
J Biol Chem; 2011 Apr; 286(13):11290-8. PubMed ID: 21297162
[TBL] [Abstract][Full Text] [Related]
16. Phosphatidylinositol 4-kinase III beta is essential for replication of human rhinovirus and its inhibition causes a lethal phenotype in vivo.
Spickler C; Lippens J; Laberge MK; Desmeules S; Bellavance É; Garneau M; Guo T; Hucke O; Leyssen P; Neyts J; Vaillancourt FH; Décor A; O'Meara J; Franti M; Gauthier A
Antimicrob Agents Chemother; 2013 Jul; 57(7):3358-68. PubMed ID: 23650168
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication.
Berger KL; Kelly SM; Jordan TX; Tartell MA; Randall G
J Virol; 2011 Sep; 85(17):8870-83. PubMed ID: 21697487
[TBL] [Abstract][Full Text] [Related]
18. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
[TBL] [Abstract][Full Text] [Related]
19. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
Aloia AL; Eyre NS; Black S; Bent SJ; Gaeguta A; Guo Z; Narayana SK; Chase R; Locarnini S; Carr JM; Howe JA; Beard MR
Antivir Ther; 2015; 20(3):271-80. PubMed ID: 25222708
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein.
Pouliot JJ; Thomson M; Xie M; Horton J; Johnson J; Krull D; Mathis A; Morikawa Y; Parks D; Peterson R; Shimada T; Thomas E; Vamathevan J; Van Horn S; Xiong Z; Hamatake R; Peat AJ
Antimicrob Agents Chemother; 2015 Oct; 59(10):6539-50. PubMed ID: 26259798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
